Election 2020: Californias ballot initiative system isnt working. – Vox.com

Finding the best ways to do good.

I live in California. And three weeks before the election, the people in my quarantine bubble sat down in our living room for a nine-hour research project: figuring out how to vote.

Not for our elected representatives or for president, but on kidney dialysis regulations and stem-cell medical research funding and whether to uphold a law passed by the legislature replacing cash bail with a risk assessment system and nine more propositions after those. My ballot was six pages long, many of them on issues Id never thought about before and, after a few frustrating hours figuring out how to vote, will never think about again.

Direct democracy can be a profound and important tool for political change, and 2020 had many examples of that. In several states, voters decriminalized drugs from marijuana to mushrooms sending a powerful message to lawmakers that their constituents are done with the war on drugs. Ive written in past years that voters are way ahead of state legislatures on banning animal cruelty. Americas electoral system definitely benefits from a place for voters to directly weigh in on issues. (My colleague Sigal Samuel has a rundown of the ballot initiatives that we should cheer in todays edition of the Future Perfect newsletter. Subscribe!)

But what it doesnt benefit from is a system like Californias, where ballots get padded out and weighted down with unclearly written ballot propositions on a dozen niche issues. Many people have been frustrated by these problems on their ballots, but California where voters have been asked to simultaneously entertain abolishing and expediting the death penalty, to weigh dueling propositions about plastic bags, to advise the state legislature to overturn US Supreme Court decisions (it cannot do that), and now, on two different occasions, to weigh in on the proper running of dialysis clinics leads the pack.

A system that funnels lots of issues, both big and small, directly to the voters leads to bad policy judgments, because under-informed voters dont have time to research and form opinions on all the issues. It leads to a handicapped legislature that cant do its job, because large sections of state law are untouchable. (In California, for instance, the legislature has to send many propositions to voters because other propositions have prohibited them from legislating directly.) When a voter-approved initiative is unclearly worded, it can cause years of uncertainty because the issue cant easily be sent back to the voters to adjust the wording.

But just because how we run ballot propositions today is a problem doesnt mean we have to give them up altogether. There is a way we can make direct democracy work.

Lets say that you dislike the work your state legislature is doing. In 26 US states and Washington, DC, you have the power to ask voters to pass laws themselves through a ballot initiative.

There are, broadly, three categories of ballot initiatives available in the states that have a citizen initiative process. In the first, citizens draw up a proposed law and put it on the ballot. If other citizens approve it, it becomes a law. In the second, citizens who disapprove of a law the legislature passed put it on the ballot to try to repeal it (called a veto referendum). In the third, citizens propose, and vote on, a change to the state constitution.

Some states only allow some of these types of initiatives, and some dont allow citizen initiatives at all. Maryland and New Mexico, for example, only allow veto referendums; Utah, Wyoming, Washington, Maine, Alaska, and Idaho allow citizens to put forth initiatives, but not constitutional amendments. Illinois, Mississippi, and Florida allow constitutional amendments but not initiatives.

The details of the process to put a new law, a veto referendum, or a constitutional amendment on the ballot varies from state to state, but in general, proponents file their proposed initiative with the state and then start collecting signatures for it. If they collect enough signatures, it goes on the ballot for the next statewide election. If it wins over enough voters at the election, it becomes a law.

Lots of important work has gotten done through ballot initiatives. But in many ways, laws passed via initiative are more problematic than laws passed by the legislature. Because they are not written by professional legislators, they are often unclearly written; many voters report being confused about what ballot initiatives they voted on will do. Many ballot measures are misleadingly structured so that a no vote represents a big, confusing change to the law, while a yes vote does nothing. There is fierce political fighting about initiatives are summarized on the ballot a process that is supposed to be apolitical, but sometimes isnt.

And while initiatives were meant to empower grassroots political movements, the system to put an initiative on the ballot is much easier for large lobbying groups to navigate, and special interest groups drive many initiatives.

In some states, like California, the sheer number of initiatives is starting to get out of hand, which worsens all of the other problems with ballot initiatives, as its easier for voters to see through one misleading proposition than through 10.

Every state does direct democracy in a different way.

But California reliably has one of the longest ballots. In 2016, there were 17 statewide initiatives. The voter guide mailed to all voters to explain them was 224 pages long.

In 2020, the threshold for initiatives to make the ballot was substantially higher (the threshold is set based on turnout in the most recent governors race, and 2018 turnout set records) and there werent as many. But voters still weighed in on bonds to pay for stem cell research, property tax changes, a repeal to the state ban on affirmative action, restoring voting rights for convicted felons, allowing 17-year-olds who will be 18 in November to vote in primaries, more property tax changes, changes to criminal sentencing, allowing rent control in more parts of the state, labor policies for ride-hailing apps, dialysis clinic regulations, a new data privacy law, and abolishing cash bail.

Those were just the statewide initiatives; voters also considered many city and countywide local initiatives. Thats 12 statewide initiatives, more than anywhere else in the country (though Colorado voters came close, with 11.)

California also had by far the most spending aimed at changing minds on ballot initiatives: $708 million in contributions, compared to $121 million in the next most-contested state. Across all 50 states, 120 ballot measures were decided on Election Day.

Californias initiative process permits all three types of resolutions (initiatives to create a new state law, initiatives to veto a state law passed through the legislative process, and initiatives to amend the constitution) and makes it much easier than many states to put an initiative on the ballot requiring just 5 percent of the number of voters who voted in the gubernatorial race in the most recent election to put an initiative on the ballot. Many states require 10 percent of the number of votes cast for governor and many states have competitive elections for governors.

Californias gubernatorial races are almost never competitive and often have very low turnout, which depresses the signature requirement further. In 2016, only 365,880 signatures were needed (in a state with 40 million people and 18 million registered voters) to add an initiative to the ballot. (High 2018 turnout raised the bar somewhat, but as a percentage of total population, its still one of Americas lowest thresholds.)

Finally, its not just easier for laws to make it onto the ballot; its also easier for them to pass. In many states amending the constitution requires a supermajority. In Florida, for example, which amended its constitution this week to raise the minimum wage, a 60 percent majority is required. In California, propositions including those amending the state constitution pass if they get more than 50 percent of the vote.

California was one of the first states that allowed citizen-driven ballot initiatives, and at first, ballot initiatives were sparse. As collecting signatures became easier, the number of California propositions has spiked especially in the last few decades. As a result, the initiative system has grown quite unwieldy and crude in ways that have perverted the initial vision, historian William Deverell at the University of Southern California said this fall.

For all of the drawbacks of ballot initiatives, the variety of different approaches to propositions in different states is a great thing one of the best examples of the state systems function as laboratories of democracy.

We now have some results from those laboratories of democracy, and they suggest that the initiative system works best when there are a manageable number of initiatives on the ballot at election time. Voter participation is higher, and voters are more able to focus their attention on a handful of meaningful, high-value issues: Should we legalize marijuana? Should we reenfranchise people who have been convicted of a crime and served their sentence? Should we change how our state votes?

When voters are snowed under with nearly a dozen propositions, including many on highly specific niche issues like kidney dialysis regulation that theyre unequipped to evaluate, participation drops, and the results become more strongly predicted by which side spent the most money probably because if voters dont have time to look things up, theyre more likely to go with what they saw on TV. The impressive successes of ballot initiatives against the war on drugs this year should have governments in every state thinking about how they can best use ballot initiatives to their full potential.

For the 14 states that dont allow any ballot initiatives, that might mean rethinking that. But for the states that allow ballot initiatives with a very low threshold, and see low participation and high voter confusion as a result, it means rethinking that, too. Promising proposals include raising the signature threshold, capping the number of propositions on the ballot, and restricting counter-propositions conflicting laws on the ballot at the same time.

Direct democracy is a part of our system because of a belief that voters deserve a direct say in how their state is run. The best implementation gives voters a few highly meaningful choices well worth their time. If we cant manage that, were not empowering voters were burdening them.

Sign up for the Future Perfect newsletter. Twice a week, youll get a roundup of ideas and solutions for tackling our biggest challenges: improving public health, decreasing human and animal suffering, easing catastrophic risks, and to put it simply getting better at doing good.

Will you help keep Vox free for all?

Millions of people rely on Vox to understand how the policy decisions made in Washington, from health care to unemployment to housing, could impact their lives. Our work is well-sourced, research-driven, and in-depth. And that kind of work takes resources. Even after the economy recovers, advertising alone will never be enough to support it. If you have already made a contribution to Vox, thank you. If you havent, help us keep our journalism free for everyone by making a financial contribution today, from as little as $3.

Read the original:
Election 2020: Californias ballot initiative system isnt working. - Vox.com

Many Initiatives Still Too Close to Call in California – Courthouse News Service

SACRAMENTO, Calif. (CN) A record 22 million Californians registered to vote ahead of the November general election. While the allure of choosing the next occupant of the White House no doubt spurred many of them to the ballot box, they also had a list of initiatives to decide ranging from whether the state should go to a split-roll property tax scheme to ending the money bail system.

The bid to end cash bail failed, but heres a look at how some of the other propositions are faring even as the vote count continues:

Proposition 15

Ignoring pleas for budget relief from Californias cash-strapped cities and Governor Gavin Newsom, voters are on the verge of rejecting a bid to amend the states landmark tax code and put the squeeze on commercial landlords.

With over 75% of the estimated total vote counted, 52% have voted no on Proposition 15 the so-called split-roll bid. The proponents dreams of raising up to $11.5 billion in new tax revenues for schools and cities is on the ropes, as the measure faces a 426,000 vote-deficit as of Friday.

If the result holds, it would be further proof of the popularity and resiliency of a voter-approved tax scheme that is credited with preventing runaway tax bills for property owners in the Golden State for decades.

Seeking to make taxes more predictable and stable, 63% of Californians voted in 1978 to amend the state constitution in order to slow tax increases for both commercial and residential property. Considered by many as the third rail of California politics, the system caps annual tax increase on both commercial and residential properties.

The tax code has remained largely unchanged despite the fact its long been a target of some of the states most influential labor unions. Former lawmakers and governors even during previous economic downturns have hardly dared to challenge the tax code, wary of its reputation.

But with the state facing a record $54 billion Covid-induced deficit, proponents have been trying to convince voters they could unearth a giant new revenue stream by raising taxes on commercial properties valued above $3 million. The supporters amassed a deep and influential bench featuring Newsom, former Vice President Joe Biden, Facebook CEO Mark Zuckerberg and many of the states largest labor unions.

Leading the fight against the tax reform are a collection of business and agricultural groups, as well as the Howard Jarvis Taxpayers Association named after the author of the original ballot measure. They cast Proposition 15 as the largest property tax increase in California history and claimed it would send commercial rents and the cost of consumer goods skyrocketing.

In the run up to the election, the sides combined to raise a staggering $139 million on Proposition 15.

To pull off a comeback in the coming days or potentially weeks, the proponents are hoping to glean more support from many of the states coastal counties in the final batches of votes.The proposition has had success thus far in counties like Los Angeles (53-47%), San Francisco (71-29%), Santa Clara (56-44%), Alameda (66-34%) and Marin (63-37%).

Proponents can find a glimmer of hope in the fact that according to the Secretary of States latest estimates, there are still nearly 1 million outstanding ballots in Los Angeles and Alameda alone. Statewide, there are an estimated 4.5 million ballots left to be counted as of Thursday evening.

Support fades inland however as voters are rejecting the split-roll scheme in counties like Fresno (40-60%), Tulare (64-36%) Riverside (40-60%) and Sacramento (53-47%). Making the comeback more difficult is the fact the measure is on course for defeat in the major coastal counties of San Diego (44-56%) and Orange (39-61%).

Mary-Beth Moylan, associate dean at University of the Pacifics McGeorge School of Law who also supervises the publication of the universitys California Initiative Review, said the opponents succeeded in hammering home their claim that increased commercial property taxes would eventually trickle down to consumers.

The no side did a good job of saying This isnt a tax that will only be against corporations, its going to impact small businesses, Moylan said.

Proposition 19

California would crack down on longstanding tax breaks for inherited homes but allow older residents the ability to take their cushy property tax rates with them when they move under a closely contested ballot measure.

In a race too close to call as of Friday morning, Proposition 19 was leading by a 51-49% margin.

Backed by Newsom along with realtor and firefighter groups, Proposition 19 is meant to give seniors wishing to move within the state more flexibility. If passed, homeowners over the age of 55 as well as those with certain disabilities and wildfire victims could keep their property tax bill with them if they sell and move to a more expensive place.

Supporters say the change could spur more seniors to downsize or move into retirement centers and carries the bonus of increasing housing supply.

Prop 19 will open up tens of thousands of homes that havent been on the market for decades, creating opportunities for new buyers and helping to stabilize housing costs so more Californians can afford home ownership, the supporters claim on their website.

The proposal, placed on the ballot by the Democrat-controlled Legislature, also purports to raise new revenue for local governments and fire departments, as it would increase the tax hit on in-family property transfers.

Led by the Howard Jarvis Taxpayers Association, the opponents argue the change would punish those simply looking to pass on family homes to their children or grandchildren. They note a similar proposal was nixed by voters in 2018.

This is a billion-dollar tax increase on California families, the taxpayers association warns. The price is too high.

Much like the related split-roll proposal, the residential tax reform proposal has performed well in the San Francisco Bay Area as well San Diego and Ventura counties. But supporters remain on edge as the measure hasnt run up more than 60% support in any county and there isnt a clear result as Proposition 19 is ahead by only 336,000 votes.

Proposition 14

Two decades after greenlighting a taxpayer-funded stem cell research agency, California voters are on the verge of approving billions more to find a cure for chronic diseases and cancers.

Ahead by a 51-49% margin, Proposition 14 would allow the state to sell up to $5.5 billion in bonds to prop the California Institute for Regenerative Medicine and its efforts to fight everything from Parkinsons disease, diabetes, stroke and infectious diseases including Covid-19.

After a ban on federal funding for stem cell research during the George W. Bush administration, researchers in 2004 turned to the state ballot. They ultimately convinced voters by a 59-41% margin to create a constitutional right to study stem cell cures as well as take on $3 billion in new debt.

Since 2004, nearly a dozen states including New York and Maryland have created similar programs but on a much smaller scale.

Now the backers seek to keep the institute afloat with another $5.5 billion infusion that could ultimately cost $7.8 billion to pay off. Supporters include Newsom, the University of California Board of Regents and the American Association for Cancer Research.

Critics countered that private stem cell research has made great strides since 2004 and that the federal funding ban was lifted under President Barack Obama. With the state mired in recession, the editorial boards of several California newspapers concluded it was bad timing for Proposition 14 and urged readers to vote no.

The latest update from the Secretary of State shows over 50% support for Proposition 14 in coastal counties like San Diego, Los Angeles and San Francisco. It has effectively been shut out of the Central Valley and rural counties.

The tight race shows that California voters are cognizant of the states shattered finances and are not overly enthusiastic about inking new bonds during a recession, said Moylan, the UOP professor. She says though the initiative is close, the critics seem to have made a persuasive pitch.

People are not in the mood for bonds; they are concerned about the finances of the state and are not feeling like expenditures or committing money down the line is a great idea, she said.

Like Loading...

Follow this link:
Many Initiatives Still Too Close to Call in California - Courthouse News Service

Doctors Consider Convalescent T Cell Therapy for COVID-19 – The Scientist

Physicians and researchers have had questionable success treating patients with severe COVID-19 with either antibody-based drugs or convalescent plasma. Neither of those strategies is a cell-based therapy, and, in a preprint posted October 26 on bioRxiv,researchers propose collecting SARS-CoV-2specific memory T cells from recovered individuals, banking the cells, and infusing them into patients as a treatment for infections.

There are data now that are coming out from the analysis of the immune response that are suggesting that the T cells are more important for protection than antibodies, says Antonio Bertoletti, who studies the development of immunological therapies at Duke-NUS Medical School in Singapore and did not participate in the work. There is therefore a rationale to use T cells to control the disease, he adds.

Previously, researchers had attempted memory T cell therapy to suppress cytomegalovirus and Epstein Barr virus. The recipients were leukemia patients who received a stem cell transplant to treat their cancer at the same time. It was this success, combined with the T cell findings from COVID-19 patients, that led Antonio Prez-Martnez, a pediatrician at Hospital Infantil Universitario La Paz in Madrid, and his colleagues to consider a cell-based treatment for the coronavirus.

The researchers isolated memory T cells, including some that released interferon gamma, a cytokine necessary for anti-viral immunity, upon exposure to SARS-CoV-2 antigens, from the blood of people who recovered from COVID-19. They showed that it was possible to freeze, store, and thaw these cells and propose that biobanks of memory T cells could be created from convalescent donors to be infused to treat disease. The practice of storing convalescent plasma, which includes antibodies but no immune cells, to treat COVID-19 patients is already in wide use, although with mixed data on its utility.

If you give plasma and antibodies, those antibodies could potentially fight COVID, but they are not produced in that person, so they are just have a normal half-life and they are cleared, says Rory de Vries, an immunologist at Erasmus University Medical Center in the Netherlands who did not participate in the study. But when T cells encounter a virus, they start expanding, and you might actually build your own new immunological memory while youre doing that, which will never happen with plasma.

Despite the theoretical potential, its not an easy approach, de Vries cautions. For one thing, the authors dont only store SARS-CoV-2 specific T cells, they store every memory cell, so that means that you also store your memory for measles or . . . previous vaccinations, he tells The Scientist. And if you infuse these T cells, I dont think we really know what might happen.

In a cell-based treatment, there are also concerns about immunological compatibility of the donor and recipient, just as there would be during an organ transplant, de Vries explains. The authors did characterize memory T cells based on human leukocyte antigens (HLA), molecules responsible for the immune systems ability to distinguish self and non-self. But de Vries cautions that HLA diversity is vast, potentially requiring more extensive characterization than the authors have done in the preprint to make the treatment safe.

According to Prez-Martnez, the HLA matching is sufficient because patients with severe COVID-19 have lymphopenia, a dearth of white blood cells called lymphocytes, a subtype of which are T cells. Lymphopenia is a biological marker of severe COVID-19, he says. The patients who are more lymphopenic have a greater chance of ending up in the ICU and eventually dying.

The lymphopenia triggered by the coronavirus is similar to the lymphopenia induced by chemotherapy drugs in patients before a stem cell transplant, so the transplant wont be rejected, he explains. This lymphopenic window during COVID-19 is the time at which it could be possible to replace a patients missing lymphocytes with SARS-CoV-2-responsive T cells from recovered donors. The idea is that lymphopenic patients dont have enough of their own T cells, so theyre not going to reject donor lymphocytes.

This strategy is complicated and needs some work, says Bertoletti. It could be that for a short time . . . when you are introducing these T cells in a patient, they will be basically able to suppress viral replication and kill the infected cells, he adds, but the unanswered questions of how important HLA matching is and what the appropriate timing for such a treatment complicates matters.

In order to test the safety of the treatment, Prez-Martnez and colleagues are beginning a Phase I clinical trial in patients hospitalized for COVID-19 with lymphopenia. In the transplant setting, doctors have not seen any side effects, he says, so I think that its worth it to try.

C. Ferreras et al., SARS-CoV-2 specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking and large-scale production for Adoptive Cell Therapy,bioRxiv, doi:10.1101/2020.10.23.352294, 2020.

Read more from the original source:
Doctors Consider Convalescent T Cell Therapy for COVID-19 - The Scientist

Canine Stem Cell Therapy Market Analysis, Latest Trends and Regional Growth Forecast by Types and Applications 2020 – TechnoWeekly

The globalCanine Stem Cell Therapy marketwas valued at US$ 118.5 Mn in 2018 and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period. With COVID-19 pandemic, many industries are transforming rapidly. The Global Canine Stem Cell Therapy Market is one of the major industries undergoing changes. This year many industries have vanished entirely from the market and many industries have risen.

Moreover, the government-backed schemes throughout the globe are offering many advantages to businesses. As the governing bodies are supporting the industries, it is a strong pillar to support the market growth of Canine Stem Cell Therapy in the upcoming decade (2020-2026). Organizations planning to move into new market segments can take the help of market indicators to draw a business plan. With the technological boom, new markets are blossoming across the globe, making it a breeding ground for new businesses.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

Global Canine Stem Cell Therapy Market 2020: Covering both the industrial and the commercial aspects of the Global Canine Stem Cell Therapy Market, the report encircles several crucial chapters that give the report an extra edge. The Global Canine Stem Cell Therapy Market report deep dives into several parts of the report that plays a crucial role in getting the holistic view of the report. The list of such crucial aspects of the report includes company profile, industry analysis, competitive dashboard, comparative analysis of the key players, regional analysis with further analysis country wise.

Global Canine Stem Cell Therapy Market Analysis by Key Players:

Any questions, Lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Moreover, one of the uniqueness in the report is that it also covers the country-level analysis of the regulatory scenario, technology penetration, predictive trends, and prescriptive trends. This not only gives the readers of the report the actual real-time insights but also gives country-wise analysis, that plays a vital role in decision making. The inclusion of the report is not limited to the above mention key pointers. The report also emphasizes on the market opportunities, porters five forces, and analysis of the different types of products and application of the Global Canine Stem Cell Therapy Market.

The report splits by major applications:

Then report analyzed by types:

Global Canine Stem Cell Therapy Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Canine Stem Cell Therapy industry, focusing on the main regions and the main countries as Follows:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @ https://www.alltheresearch.com/impactC19-request/206

Table of Contents Includes Major Pointes as follows:

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/206/Canine Stem Cell Therapy

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Read the original here:
Canine Stem Cell Therapy Market Analysis, Latest Trends and Regional Growth Forecast by Types and Applications 2020 - TechnoWeekly

Stem Cell Therapy Market 2020: Size, Professional Survey, and Forecast to 2025 – PRnews Leader

This report on global Stem Cell Therapy market primarily focuses on multi-faceted attributes comprising dynamic untapped market opportunities, end-user profile, vendor landscape, historical and current market status that collectively foster high end growth and sturdy revenue generation with concrete sustenance in global Stem Cell Therapy market. This in-depth research documentation is aimed at unfurling notable development factors and growth propellants that steer growth prospects despite challenging odds and intensified competition.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=PN

To induce a more concrete, real-time synopsis of the current dynamics dominating the global Stem Cell Therapy market, this versatile report attempts to offer a decisive rundown of the major segments comprising of type, application as well as end-user profile, and regional expanse that collectively dominate future growth outlook in global Stem Cell Therapy market.

This future ready report closely monitors and assesses the role of various driving factors and restraints coupled with challenge assessment and elaborate SWOT and PESTEL analysis to arrive at logical deductions. Further in this report, readers are also presented with a 360degree assessment and evaluation of the competition spectrum, emphasizing frontline player activities and investment plans which collectively influence favorable transit in CAGR valuation through the forecast tenure.

Any questions, Lets discuss with the analyst @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=PN

Global Stem Cell Therapy market is segmented based by type, application and region.

Stem Cell Therapy Market segment by Type, the product can be split into

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Stem Cell Therapy Market segment by Application, split into

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The report is designed specifically to entice reader attention towards identification and analysis of the chief growth propellants as well as dominant restraints and associated forces that optimally trace growth trajectory in global Stem Cell Therapy market.

Besides corrective measures, this intricate research report presentation on global Stem Cell Therapy market as compiled by our inhouse research professionals also features details on CAGR percentage, consumption and production patterns, as well as demand and supply gaps that have been immediate outcome of pandemic emergence and its lingering state.

Besides tracing direct implications of COVID-19 on the aforementioned Stem Cell Therapy industry that have affected production, consumption and overall supplychain, this report also shares critical understanding on the effective evolution scheme likely to elevate manufacturers and stakeholders from debilitating pandemic implications.

To know More Details About Stem Cell Therapy Market research Report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=PN

Further, our team of research professionals have closely followed primary and secondary research methodologies to scout multi-layered information across disparate sources ranging from corporate sources, analytical solution providers, processing institutions to understand and comprehend value chain developments.

This report on global Stem Cell Therapy market primarily focuses on multi-faceted attributes comprising dynamic untapped market opportunities, end-user profile, vendor landscape, historical and current market status that collectively foster high end growth and sturdy revenue generation with concrete sustenance in global Stem Cell Therapy market. This innovative research documentation is aimed at unfurling notable development factors and growth propellants that steer growth prospects despite challenging odds and intensified competition.

Reasons to buy:

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

* Classify potential new clients or partners in the target demographic.

* Develop tactical initiatives by understanding the focus areas of leading companies.

* Plan mergers and acquisitions meritoriously by identifying Top Manufacturer.

* Formulate corrective measures for pipeline projects by understanding Stem Cell Therapy pipeline depth.

* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.

* Report will be updated with the latest data and delivered to you within 2-4 working days of order.

* Suitable for supporting your internal and external presentations with reliable high quality data and analysis.

* Create regional and country strategies on the basis of local data and analysis.

Inquire Before Buying Or Ask For Custom Requirement @ https://www.adroitmarketresearch.com/researchreport/purchase/691?utm_source=PN

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read the original post:
Stem Cell Therapy Market 2020: Size, Professional Survey, and Forecast to 2025 - PRnews Leader

Cancer Stem Cell Therapy Market: Industry Trends and Developments 2020-2025 – Zenit News

Market Overview of Cancer Stem Cell Therapy Market

The Cancer Stem Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Cancer Stem Cell Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2802065&source=atm

Market segmentation

Cancer Stem Cell Therapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

segment by Type, the product can be split into Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Other

Market segment by Application, split into Hospital Clinic Medical Research Institution Other

Based on regional and country-level analysis, the Cancer Stem Cell Therapy market has been segmented as follows: North America United States Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Latin America Mexico Brazil Middle East & Africa Turkey Saudi Arabia UAE Rest of Middle East & Africa

Regional analysis is another highly comprehensive part of the research and analysis study of the global Cancer Stem Cell Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Cancer Stem Cell Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Cancer Stem Cell Therapy market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2802065&source=atm

The report offers in-depth assessment of the growth and other aspects of the Cancer Stem Cell Therapy market in important countries (regions), including:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, etc.)

Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Cancer Stem Cell Therapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Cancer Stem Cell Therapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Cancer Stem Cell Therapy sales, revenue and market share for each player covered in this report.

In the competitive analysis section of the report, leading as well as prominent players of the global Cancer Stem Cell Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. The key players covered in this study AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2802065&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Cancer Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Cancer Stem Cell Therapy , with price, sales, revenue and global market share of Cancer Stem Cell Therapy in 2018 and 2019.

Chapter 3, the Cancer Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cancer Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.

Chapter 12, Cancer Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.

Chapter 13, 14 and 15, to describe Cancer Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Link:
Cancer Stem Cell Therapy Market: Industry Trends and Developments 2020-2025 - Zenit News

The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology – The Think Curiouser

Adipose tissue is rich in multi potent stem cells that have the capability to differentiate into a number of cell types including adipocytes, osteocytes, chondrocytes and others, in vitro. These Adipose Tissue-derived Stem Cells are used for a number of applications including stem cell differentiation studies, regenerative medicine, cell therapy, tissue engineering and development of induced pluripotent stem cell lineage. Adult stem cells such as the Adipose Tissue-derived Stem Cells have a very good potential for regenerative medicine. The Adipose Tissue-derived Stem Cells show higher yields compared with other stem cell sources. Some of the regenerative medicine applications using Adipose Tissue-derived Stem Cells include skin, bone and cartilage regeneration.

For more insights into the Market, request a sample of this report @https://www.persistencemarketresearch.com/samples/25831

Although, Adipose Tissue-derived Stem Cells have the ability to differentiate into different cell types in vitro, unlike the embryonic stem cells they lack the ability to differentiate into all types of organs and tissues of the body. Derivation of stem cells from adipose tissue have a number of advantages including that fat tissue contain 100 to 1000 times more mesenchymal stem cells than the bone marrow. Furthermore the method of collection of fat tissue is relatively easier and is less invasive than that of bone marrow collection. Although Adipose Tissue-derived Stem Cells have a potential to be used in cell-based therapy, there are a number of challenges the Adipose Tissue-derived Stem Cells market has to face. Some of the challenge include the safety issue for the clinical use of Adipose Tissue-derived Stem Cells, development and differentiation of the cells, delivery of the cells in vivo and immune response after the transplant.

For Information On The Research Methodology request here @https://www.persistencemarketresearch.com/methodology/25831

The global Adipose Tissue-derived Stem Cells market is segmented based on product type and end user. Based on product type the Adipose Tissue-derived Stem Cells can be categorized into cell line and reagent & kits. Cell line can be further classified based on the source of the adipose tissue such as human and rodents. Based on reagents the Adipose Tissue-derived Stem Cells market is further classified as media & sera and kits. Based on application the Adipose Tissue-derived Stem Cells market is classified into regenerative medicine, cell therapy, tissue engineering, and other applications such as cell differentiation studies and other similar research. End users of Adipose Tissue-derived Stem Cells market are biotechnology companies and academic and research institutes.

The Global Adipose Tissue-derived Stem Cells market is classified on the basis of product type, end user and region:

Based on the Product Type, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the application, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the end user, Adipose Tissue-derived Stem Cells market is segment as below:

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/25831

Growing research activities using stem cells along with the growth of regenerative medicine and cell therapy the global Adipose Tissue-derived Stem Cells market is set to expand considerably during the forecast period. However, ethical concerns and stringent regulations may hinder the growth of the global Adipose Tissue-derived Stem Cells market.

On the basis of geography, global Adipose Tissue-derived Stem Cells market is segmented into six major regions that include North America, Latin America, Europe, Asia-Pacific excluding China, China and Middle East & Africa. North America is expected to be the most lucrative Adipose Tissue-derived Stem Cells market owing to increased research activity of stem cells. Furthermore government support for regenerative and stem cell based studies along with cell therapy studies is driving the growth of the Adipose Tissue-derived Stem Cells market in the region. Changing government regulations in china is supporting the research activity that supports the growth of the adipose tissue-derived stem cell market in the region at a considerable rate.

Key participants operating in the Adipose Tissue-derived Stem Cells market are: Lonza, ThermoFisher Scientific, Celprogen, Inc, American CryoStem, Rexgenero Ltd, iXCells Biotechnologies, Merck KGaA, Lifeline Cell Technology, and others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

Excerpt from:
The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser

Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease – GlobeNewswire

November 06, 2020 08:35 ET | Source: Equillium

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

Complete response observed in seven of eight responding patients

EQUATE Phase 1b topline data expected during first half 2021

LA JOLLA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease (aGVHD). The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication. Equillium anticipates reporting topline data across all cohorts from the Phase 1b portion of the EQUATE trial during the first half of 2021 and is accelerating plans for further development of itolizumab in graft-versus-host disease.

In the EQUATE trial, the overall response rate across the first three dose cohorts was 80%, and seven of eight patients responding achieved a complete response (CR) and one patient achieved a very good partial response (VGPR) by Day 29 (VGPR approximates the clinical benefit of CR). Responses observed have been rapid, with most patients achieving a CR within the first 15 days, and durable as patients in the first two cohorts have maintained responses through Day 57. To date, adverse events reported with the EQUATE trial have been consistent with the safety profile previously reported for itolizumab and those common in the aGVHD patient population. In review of the totality of safety, efficacy and pharmacodynamic data, the independent data monitoring committee has recommended to expand cohort 3 (1.6 mg/kg dose) and proceed forward with enrollment.

We continue to accrue compelling data in the EQUATE trial the rapid and durable response rates in patients treated with itolizumab meaningfully exceeds what has been observed in patients with severe aGVHD treated with steroids alone, said Bruce Steel, chief executive officer of Equillium. We plan to engage the U.S. Food and Drug Administration (FDA) to explore expedited regulatory pathways to advance itolizumab for the first-line treatment of aGVHD. Further, this data suggests opportunities to expand the potential therapeutic application of itolizumab for patients with chronic GVHD and as a potential preventative treatment for patients who have undergone hematopoietic stem cell transplantation. We believe itolizumab has the potential to be a life-saving medicine for aGVHD patients, a severe and life-threatening illness for which there are currently no approved therapeutics.

Equillium has received fast track designation from the FDA for the treatment of itolizumab in patients with aGVHD and orphan drug designations from the FDA for both the prevention and treatment of aGVHD. Equillium plans to provide additional updates on the program at its upcoming analyst day on December 4, 2020.

About Graft-Versus-Host Disease GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipients body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.

GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and the risk of GVHD limits the number and type of patients receiving HSCT. GVHD results in very high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. In the first-line aGVHD setting, published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in less severe standard risk patients as 69% overall response rate (ORR) and 48% CR, whereas in more severe high-risk patients response rates observed were 43% ORR and 27% CR.

About the EQUATE Study The EQUATE study is a Phase 1b/2 trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab for first-line treatment in patients who present with aGVHD (NCT 03763318). The Phase 1b part of the trial is an open-label dose escalation study in adult patients who present with severe aGVHD (Grades III and IV) and typically respond poorly to steroids. The Phase 1b data will inform selection of the dose to be used in the next phase of development for the program.

About Itolizumab Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including aGVHD, lupus nephritis, uncontrolled asthma, and will soon be evaluated in a clinical trial of patients with COVID-19. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is marketed in India under the trade name ALZUMAb-L for the treatment of chronic plaque psoriasis and has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including COVID-19, aGVHD, lupus nephritis and uncontrolled asthma.

For more information, visitwww.equilliumbio.com.

Forward Looking Statements Statementscontained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limitedto, the potential benefit of treating aGVHD or chronic GVHD patients, as well as patients who have undergone hematopoietic stem cell transplantation, with itolizumab, Equilliums business strategy, Equilliums plans and expected timing for developing itolizumab, including theexpected timingofcompletion of theEQUATE study and initiating a clinical trial in patients with COVID-19,the potential for interim data results to be consistent with final results, once available,the potential benefits of itolizumab, the potential for any ofEquilliumsongoingor plannedclinical trials to show safety or efficacy, and the impact of the COVID-19 pandemic. Risks that contribute to the uncertain nature of the forward-looking statements include:the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom;the risk thatstudies willnot becompletedas planned;uncertainties related to Equilliums capital requirements; Equilliums plans and product development, including the initiation, restarting and completion of clinical trials; uncertainties related to the actual impacts and length of such impacts caused by the COVID-19 pandemic; uncertainties caused by the recent restarting of the EQUIP and EQUALISE clinical trials after a pause; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab;andhaving to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact Christine Zedelmayer, Chief Operating Officer +1-858-412-5302 ir@equilliumbio.com

Media Contact Katherine Carlyle Smith Senior Account Associate Canale Communications 805-907-2497 katherine.smith@canalecomm.com

Continue reading here:
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease - GlobeNewswire

Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma – Curetoday.com

Several drugs that work by targeting genetic alterations in cancer cells have won recent approval from the Food and Drug Administration as treatments for patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Germame Ajebo, assistant professor of medicine at Georgia Cancer Center at Augusta University, shared information on novel treatments for the disease during the recent virtual CURE Educated Patient Leukemia & Lymphoma Summit.

In his talk, Ajebo focused on drugs meant for use in disease that has recurred or become resistant to previous treatments.

DLBCL is a usually aggressive form of the blood cancer known as a B-cell non-Hodgkin lymphoma, which affects the immune system. The disease causes rapid growth of tumors in the lymph nodes, spleen, liver, bone marrow or other organs.

Approved by the FDA within the last two years to treat aggressive DLBCL are oral Xpovio (selinexor), Polivy (polatuzumab vedotin-piiq) and Monjuvi (tafasitamab-cxix). In addition, an immunotherapy, the chimeric antigen receptor (CAR)-T cell therapy Yescarta (axi-cel), was approved to treat the disease in 2017, Ajebo reported.

Read more: Monjuvi-Revlimid Combination Approval Fills Unmet Need for Certain Patients with DLBCL.

Xpovio is a nuclear export inhibitor, which prevents cancerous cells from pushing tumor-suppressing proteins out of their nuclei. This results in tumor suppressors accumulating in the nucleus, where they can work to kill the cell.

In the phase 2b clinical trial that led to its approval which administered Xpovio by itself to 134 previously treated older adult patients the partial response rate (including those with tumor shrinkage) was 16%, the complete response rate (including those with no sign of cancer remaining) was 13% and the rate of stable disease (including patients with no progression of cancer) was 8.2%, Ajebo reported. Looking at all patients who had partial or complete responses, 38% responded for at least six months and 15% for at least 12 months.

The most common side effects that were serious or worse were low blood counts, Ajebo summarized. Other serious side effects included nausea, vomiting, diarrhea, weight loss, dizziness and infections.

Polivy is an antibody-drug conjugate that uses a targeted drug to deliver a potent chemotherapy directly to cancer cells.

It was approved based on the results of a phase 2 study of 80 previously treated patients who were divided into equally sized groups to receive the chemotherapy Treanda (bendamustine) and the targeted drug Rituxan (rituximab) with or without Polivy every 21 days for six cycles. At the end of treatment, 40% of those receiving the triplet combination had experienced a complete response, compared with 18% of those receiving Treanda and Rituxan alone. In the 63% of patients who achieved a best overall response at any point in the study while receiving the drug triplet, 48% had a response that lasted at least 12 months and 64% responded for at least six months, Ajebo noted.

Major side effects, he said, included tingling or weakness in the extremities, low blood counts, liver toxicity and tumor lysis syndrome, a condition that can damage organs due to blood chemistry issues arising from the quick destruction of tumor cells. The most common side effects of any severity included low blood counts, fatigue, diarrhea and fever.

Monjuvi, a targeted drug that inhibits the activity of the DLBCL-fueling protein CD19, was approved based on results of the phase 2 L-MIND study that demonstrated a 43% complete response rate and an 18% partial response rate in 80 previously treated adult patients who were prescribed the drug along with the targeted medication Revlimid (lenalidomide), with a median duration of response of 21.7 months. The drug is approved in combination with Revlimid for patients with recurrent or resistant DLBCL who are not eligible for, or did not agree to undergo, bone marrow transplant using their own stem cells, Ajebo said.

Serious side effects occurred in 52% of patients, he said, and included low blood counts and infections. The drug caused fatal reactions in 5% of patients, including stroke, respiratory failure, progressive multifocal leukoencephalopathy (a virus that infects the brain) and sudden death.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read more:
Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma - Curetoday.com

Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American…

November 05, 2020 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

BOSTONandLONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced the presentation of new clinical data at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting to be held virtually December 5-8, 2020. The oral presentation will highlight data from the first patient treated in the ongoing proof-of-concept study of OTL-201, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy being studied for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

MPS-IIIA is a progressive, life-threatening metabolic disease with no approved treatment options, said Professor Robert Wynn, chief investigator at The Royal Manchester Childrens Hospital, part of Manchester University NHS Foundation Trust. We are pleased to see encouraging initial results, including evidence of engraftment of gene-modified cells, an important first step in the investigation of whether OTL-201 could address critical unmet needs for patients with MPS-IIIA. We look forward to continuing to advance this program to add to the growing body of evidence supporting the use of HSC gene therapy to treat severe neurometabolic conditions.

Preliminary results from the first patient treated with OTL-201 show evidence of engraftment of gene-modified cells, supra-physiological N-sulphoglucosamine sulphohydrolase (SGSH) enzyme expression in multiple lineages, and reduction of heparan sulfate in plasma, cerebrospinal fluid and urine over an initial three-month follow-up period. Additional follow-up data and an update on the trial status will be shared at the time of the oral presentation.

Oral Presentation Details:

Ex-Vivo Autologous Stem Cell Gene Therapy Clinical Trial for Mucopolysaccharidosis Type IIIA: Trial in Progress NCT04201405 Publication number: 676 Session: 801. Gene Editing, Therapy and Transfer I Date and time: Monday, December 7, 2020; 12:45 p.m. PT

Abstracts are available online at the ASH Annual Meeting website.

About OTL-201 and MPS-IIIA Mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A) is a rare and life-threatening metabolic disease. People with MPS-IIIA are born with a mutation in the N-sulphoglucosamine sulphohydrolase (SGSH) gene, which, when healthy, helps the body break down sugar molecules called mucopolysaccharides, including heparan sulfate. The buildup of mucopolysaccharides in the brain and other tissues leads to intellectual disability and loss of motor function. MPS-IIIA occurs in approximately one in every 100,000 live births. Life expectancy of children born with MPS-IIIA is estimated to be between 10-25 years.1 There are currently no approved treatment options for MPS-IIIA. OTL-201 is an investigational ex vivo autologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-IIIA. It uses a modified virus to insert a functional copy of the SGSH gene into a patients cells.

About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

About Manchester University NHS Foundation Trust Manchester University NHS Foundation Trust is one of the largest NHS trusts in England and a leading provider of specialist healthcare services. Its nine hospitals are home to hundreds of world class clinicians and academic staff committed to finding patients the best care and treatments. More information is available at http://www.mft.nhs.uk.

Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter andLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, and the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedSeptember 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

1Lavery, C., Hendriksz, C.J. & Jones, S.A. Mortality in patients with Sanfilippo syndrome. Orphanet J Rare Dis 12, 168 (2017) doi:10.1186/s13023-017-0717-y

Excerpt from:
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American...